NYSE:GILD News 23 January 2026

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.

23 January 2026

Biotechnology·NYSE:GILD·NYSE:JNJ·NYSE:MRK·Pharmaceutical News·Stock Market

Novartis stock heads into Monday with Kisqali Canada nod and $23 billion U.S. R&D build-out in focus

7 February 2026

Novartis shares closed up 0.6% in Zurich at 119.96 francs Friday, with U.S. ADRs gaining 1.5%. The company broke ground on a new San Diego research center and reported a positive draft reimbursement recommendation for Kisqali in Canada. Investors are watching for the March 6 annual meeting and March 10 ex-dividend date tied to a proposed 3.70-franc payout.

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026

AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.

Wells Fargo stock jumps to $93.97 — here’s what could move WFC next week

7 February 2026

Wells Fargo shares rose 2.63% to $93.97 Friday as U.S. stocks rebounded. The stock traded ex-dividend for a $0.45 payout due March 1. Investors await delayed U.S. jobs and inflation data next week and a scheduled CFO appearance at a bank conference.

Merck stock ends week near highs after Canada clears ENFLONSIA; insider sales surface

7 February 2026

Merck shares closed up 1.8% at $121.93 Friday after Health Canada approved its ENFLONSIA RSV antibody for infants. Guggenheim raised its price target to $140. Insider filings showed three executives sold shares this week. Merck’s stock ended just below its 52-week high, with about 13 million shares traded.

NYSE:GILD News 23 January 2026

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Stock Market Today

Novartis stock heads into Monday with Kisqali Canada nod and $23 billion U.S. R&D build-out in focus

AstraZeneca stock price: What could move AZN next week as earnings loom

Wells Fargo stock jumps to $93.97 — here’s what could move WFC next week

Merck stock ends week near highs after Canada clears ENFLONSIA; insider sales surface